|Mr. Jack Weinstein||CFO & Treasurer||N/A||N/A||1956|
|Dr. Gilles Della Corte||Chief Medical Officer||107.23k||N/A||1955|
|Mr. Christiaan L. J. J. Stijnen||Chief Commercial Officer||N/A||N/A||1963|
|Dr. Taneli Jouhikainen M.B.A., M.D.||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Jeremy Meinen||VP of Fin. & Admin.||N/A||N/A||N/A|
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications is being investigated in two U.S. Phase 2b/3 clinical trials in acute respiratory deficiency due to COVID-19, as well as in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also involved in clinical development of RLF-100 for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.
Relief Therapeutics Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.